|
The adverse experiences from these studies considered by the investigators as possibly, probably, or definitely drug related in 1% of patients treated with either once weekly FOSAMAX 35 mg, FOSAMAX 5 mg/ day or placebo are presented in the following table. 
Concomitant use with estrogen/ hormone replacement therapy
In two studies (of one and two years' duration) of postmenopausal osteoporotic women (total: n= 853), the safety and tolerability profile of combined treatment with FOSAMAX 10 mg once daily and estrogen ± progestin (n= 354) was consistent with those of the individual treatments. Text Continues Below
Treatment of glucocorticoid-induced osteoporosis
In two, one-year, placebo-controlled, double-blind, multicenter studies in patients receiving glucocorticoid treatment, the overall safety and tolerability profiles of FOSAMAX 5 and 10 mg/ day were generally similar to that of placebo. The adverse experiences considered by the investigators as possibly, probably, or definitely drug related in 1% of patients treated with either FOSAMAX 5 or 10 mg/ day or placebo are presented in the following table. 
The overall safety and tolerability profile in the glucocorticoid-induced osteoporosis population that continued therapy for the second year of the studies (FOSAMAX: n= 147) was consistent with that observed in the first year. Paget's disease of bone In clinical studies (osteoporosis and Paget's disease), adverse experiences reported in 175 patients taking FOSAMAX 40 mg/ day for 3-12 months were similar to those in postmenopausal women treated with FOSAMAX 10 mg/ day. However, there was an apparent increased incidence of upper gastrointestinal adverse experiences in patients taking FOSAMAX 40 mg/ day (17.7% FOSAMAX vs. 10.2% placebo). One case of esophagitis and two cases of gastritis resulted in discontinuation of treatment. Page: << Prev | 1 | 2 | 3 | 4 | Next >>
|
.gif)
